Particle.news
Download on the App Store
3 ARTICLES
·
yesterday

GLP-1 Drugs Associated with Reduced Obesity-Related Cancer and Mortality Risks

Data from 170,000 U.S. adults indicate that GLP-1 RA prescriptions reduce colon and rectal cancer risks by up to 28%

Image
Image

Overview

  • Use of GLP-1 receptor agonists was linked to a 7% lower incidence of 14 obesity-related cancers and an 8% reduction in all-cause mortality compared to DPP-4 inhibitors over a 3.9-year follow-up.
  • Colon cancer cases fell by 16% and rectal cancer cases by 28% among GLP-1 RA users, marking the only individual cancers with statistically significant declines.
  • Women experienced an 8% drop in obesity-related cancer incidence and a 20% decline in all-cause mortality, while risk reductions in men did not reach statistical significance.
  • Researchers employed propensity score matching across 85,015 pairs of adults with obesity and diabetes treated between 2013 and 2023 to isolate the effect of GLP-1 therapies.
  • The large observational findings, to be presented at the 2025 ASCO Annual Meeting, signal potential oncologic benefits and underscore the need for prospective trials to confirm causality and mechanisms.